Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Related to this article

AI oncology data, trispecifics, nitrosamine testing: what three new deals mean for CMC and QA teams.

October 23rd, 2026

Why BMS, Roche, and LGM Pharma Outsourced Key Capabilities

BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.

October 22nd, 2026

Rare Pediatric PRVs: Manufacturing Strategies for Expedited Approval, Part 2: CMC and Regulations

Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.

October 22nd, 2026

Ask the Expert: Choosing Ingredient Suppliers

Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.

FDA approves GSK’s bepirovirsen for hepatitis B, putting antisense oligonucleotide scale-up in focus.

October 21st, 2026

FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note

FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.

OpenAI acquires Orchestra Bio, adding AI agents for drug program coordination to its Rosalind suite.

October 20th, 2026

OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio

OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.

Roche, Merck KGaA, and Lilly deals in ADCs, siRNA, and lipid nanoparticles reshape drug production.

October 19th, 2026

Three Targeted Delivery Deals: What CMC Teams Should Watch

Roche-Hansoh, Merck KGaA-Silence, and Lilly-METiS deals show how ADCs, siRNA, and lipid nanoparticles reshape demands on CMC and manufacturing teams.

Outsourcing Outlook

Articles in this issue

Related to this article

Trending on Pharmaceutical Technology

Why AI Model Updates Need Change Control: AAPS PharmSci 360 2026

AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data

From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly

PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization

AAPS PharmSci 360 2026: AI Tools, Regulations, and Preparedness